Risk Stratification Using Octreotide Test for Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results of Prospective Validation of the Test

#305

Introduction: We recently demonstrated that a plasma CgA decrement >30% after octreotide s.c. injection is a simple criterion for treatment with Somatostatin analogues (SSA) of gastroenteropancreatic endocrine tumors.

Aim(s): To evaluate prognostic value of octreotide test (OT) in a prospective cohort of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Materials and methods: From January 2008 to June 2010, we prospectively evaluated 43 consecutive newly diagnosed GEP-NET patients, receiving octreotide 200 µg s.c., with plasma CgA determination at zero, three and six hours. Patients with CgA decrement >30% were considered responsive to the test. Long-term SSA treatment was then given by monitoring clinical outcome.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Massironi S, Spampatti M, Rossi R, Conte D, Ciafardini C,

Keywords: gastroenteropancreatic neuroendocrine tumors (GEP-NETs), octreotide test (OT), prognosis ,